PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1709500
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1709500
REPORT HIGHLIGHTS
Amniocentesis Needle Market size was valued at USD 192.85 Million in 2024, expanding at a CAGR of 7.20% from 2025 to 2032.
The amniocentesis needle is a medical equipment used to perform complex diagnostic procedures on pregnant patients. This medical procedure for prenatal diagnosis involves carefully injecting a needle into the abdomen of a pregnant women. The needles passing through can be seen on the ultrasound device used by the medical professional performing this complex procedure. This amniocentesis needle is physically long and thin, allowing for precision in the procedure. It is used on pregnant women to extract amniotic fluids from the uterus that surround the fetus inside the uterus.
Amniocentesis Needle Market- Market Dynamics
Growing Advancements in Medical Devices and Technology
Increasing technological innovations in medical devices propel market growth in the amniocentesis needle market through increased safety, precision, and efficiency. Advances such as better needle design and ultrasound imaging minimise procedural risk and enhance precision during amniocentesis. In addition, research and development activities create new materials and methods that render these devices more dependable. As medical professionals gain more assurance in utilising these cutting-edge equipment, the need for amniocentesis needles increases and eventually fuels the overall development of the market as well as enhancing prenatal diagnostic results among patients. For instance, in March 2021 Becton, Dickinson and Company presented the BD Chorionic Villus Sampling (CVS) System, which features an enhanced ergonomic grip designed to reduce hand fatigue and improve precision during amniocentesis procedures.
Amniocentesis Needle Market- Key Insights
According to our research analyst, the global Amniocentesis Needle Market is expected to develop at a CAGR of approximately 7.20% between 2025-2032.
Segmented by type. In 2024, the 100-150 mm category dominated the market.
Based on procedure segmentation, the amniocentesis procedures industry generated the most income in 2024.
Based on region, in 2024, North America was the region with the highest revenue.
The global amniocentesis needle market is divided into four categories: type, procedure, end user, and region.
Based on type, the market is categorised into 100-150 mm, Larger than 150 mm, and Smaller than 100 mm. The 100-150 mm segment had the highest market share in 2023. This can be due to their adaptability and usefulness for a wide range of medical applications, including vaccines, medication delivery, and blood drawing. They strike a compromise between precision and patient comfort, making them the favored option in the medical field. These needles, in particular, are often utilised for females with a normal body mass index (BMI), as well as for pregnant women with a high BMI. For example, in the United Kingdom, a high obesity incidence poses a substantial obstetric difficulty, affecting 21.3% of pregnant women, with only 47.3% having a normal BMI. This needle is predicted to become more widely used in obstetric practice.
By Procedure, the market is segregated into Amniocentesis, Amnioreduction, Fetal Blood Transfusion, Amnioinfusion, and Cordocentesis. The amniocentesis procedures sector had the highest revenue share in 2023. This expansion can be ascribed to amniocentesis, an important prenatal diagnostic method that provides information about fetal health, genetic disorders, and chromosomal abnormalities, which is critical for pregnant parents and healthcare providers. In recent years, advances in amniocentesis techniques, including non-invasive prenatal testing (NIPT) and improved genetic testing technology, have increased the scope and precision of the procedure. For example, the expanding use of NIPT delivers very accurate genetic information without the invasiveness of other treatments. The rising maternal age and increased knowledge of genetic diseases have also spurred demand for such prenatal examinations.
Amniocentesis Needle Market- Geographical Insights
Geographically, the Amniocentesis Needle Market is distributed throughout North America, Asia Pacific, Latin America, Europe, the Middle East, and Africa. These regions are further divided based on the nations bringing in business.
North America led the global market in 2024. This can be ascribed to established healthcare infrastructure, improved prenatal care facilities, and pregnant parents' high awareness of the need for prenatal testing. Prenatal screening is becoming more popular in the United States and Canada as couples want to assess their unborn child's health and detect genetic disorders and chromosomal abnormalities. The availability of improved diagnostic tools and innovative genetic testing procedures in North American healthcare institutions has significantly contributed to the region's dominant position in this field.
The Asia-Pacific region is predicted to experience the fastest growth during the projection period. This advancement is being driven by heightened knowledge of prenatal care and the significance of genetic screening. Countries with vast populations, such as China and India, are experiencing an increase in demand for improved prenatal diagnostics. Pregnant women in Asian countries are more likely to seek complete prenatal care. Furthermore, ongoing technical improvements in the region, as well as the emergence of telemedicine and digital healthcare solutions, are increasing the availability of prenatal testing services.
The competitive dynamics of the amniocentesis needle market are influenced by a combination of veteran medical device players and new players with a focus on innovation. Major players like CooperSurgical, Integra LifeSciences, Smiths Medical, Medline, and Cook Medical control the market, with a variety of high-quality amniocentesis needles with a focus on safety and accuracy. These firms spend heavily on research and development to improve product attributes and maintain regulatory compliance. New entrants are also launching innovative technologies, including ultrasound-guided needles, that enhance procedure accuracy and safety. This competition creates a climate of continuous improvement and encourages the use of amniocentesis needles by healthcare providers, ultimately improving patient care. For instance, in June 2021, according to Medtronic pic, a medical technology pioneer, construction on a new campus in Lafayette, Colorado, has officially begun. This new facility, which is set to open in June 2021, will bring employees from the Boulder and Louisville locations under one roof. Medtronic's manufacturing activities will continue to be based in Boulder and Louisville.
April 2023, Rocket Pharmaceuticals, a prominent biotechnology business, has announced an increase in its leadership team to support its expanding and industry-leading portfolio of AAV and LV gene therapy assets.
June 2023, Becton Dickinson & Company has completed the sale of its surgical instruments, laparoscopic instrumentation, and sterilisation container assets to STERIS plc.
February 2022, CooperSurgical successfully bought Cook Medical's reproductive health business for a large sum of USD 875 million. This portfolio includes a variety of medical equipment for fertility, obstetrics, gynecology, and in vitro fertilisation (IVF).